PATHWAY
Still's disease : Treatment of systemic-onset juvenile idiopathic arthritis (SJIA)
The juvenile form of Still's disease is known as systemic-onset juvenile idiopathic arthritis (SJIA).
Search Results
All Content Formulary Only Other ContentWe have found 17 results when searching "Tocilizumab"
PATHWAY
Giant Cell Arteritis : Treatment of Giant Cell Arteritis
PATHWAY
Juvenile Idiopathic Arthritis (JIA) : Treatment of JIA with biologics and targeted synthetic DMARDs
Juvenile Idiopathic Arthritis (JIA) includes oligoarthritis, rheumatoid factor (RF)+ polyarthritis, RF- polyarthritis, Enthesitis related JIA, psoriatic or IBD associated JIA. Refer to BNF for childre...
PATHWAY
Rheumatoid Arthritis : Treatment of Rheumatoid Arthritis with biologics and targeted synthetic DMARDs
DOCUMENT
27/03/2024 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 27 March 2024 Page 1 of 11 East Region Formulary Committee Minutes Date: 27 March 2024 Time: 2.00pm – 4.00pm Location: MS Teams Present: Carla Capaldi ...
DOCUMENT
02/10/2024 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 02 October 2024 Page 1 of 12 East Region Formulary Committee Minutes Date: 02 October 2024 Time: 2.00pm – 3:15pm Location: MS Teams Present: Carla Capaldi ...
DOCUMENT
21/01/2026 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 21 January 2026 Page 1 of 9 East Region Formulary Committee Minutes Date: 21 January 2026 Time: 2.00pm – 3:50pm Location: MS Teams Present: Alison Casey Seni...
DOCUMENT
07/06/2023 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 7 June 2023 Page 1 of 17 East Region Formulary Committee Minutes Date: 7 June 2023 Time: 2pm – 4pm Location: MS Teams Present: Jane Browning (Acting) Assoc...
FORMULARY DECISION
Tocilizumab : Tocilizumab
TA375 (SMC 593/09) : Moderate to severe active rheumatoid arthritis
FORMULARY DECISION
Tocilizumab : Tocilizumab
754/12 : For the treatment of systemic Juvenile Idiopathic Arthritis